Research Papers:
Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
Metrics: PDF 1699 views | HTML 3474 views | ?
Abstract
Jieying Li1, Jianfei Huang1, Fang Huang1, Qing Jin1, Huijun Zhu1, Xudong Wang2, Meng Chen3
1Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
2Department of Laboratory Medicine & Department of Clinical Tissue Bank, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
3Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, USA
Correspondence to:
Xudong Wang, email: [email protected]
Keywords: gastrointestinal cancer, IDH1-R132H, prognosis, tissue microarray, immunohistochemistry
Received: April 25, 2016 Accepted: August 25, 2016 Published: September 15, 2016
ABSTRACT
Isocitrate dehydrogenase (IDH1) is an NADP-dependent enzyme that catalyzes the decarboxylation of isocitrate to alpha-ketoglutarate. The IDH1-R132H mutation predicts a better clinical outcome for glioma patients, and the expression of IDH1-R132H correlates with a favorable outcome in patients with brain tumors. Here, we investigated IDH1-R132H expression in both gastric (n=526) and colorectal (n=399) tissues by performing immunohistochemistry analyses on tissue microarrays. We also tested whether IDH1-R132H expression correlated with various clinical parameters. In both gastric and colorectal cancer, expression of IDH1-R132H was associated with tumor stage. Patients with low IDH1-R132H expression had a poor overall survival. Our data indicate that IDH1-R132H expression could be used as a predictive marker of prognosis for patients with gastrointestinal cancer.
![Creative Commons License](/images/80x15.png)
PII: 12039